SOX10 expression distinguishes desmoplastic melanoma from its histologic mimics

American Journal of Dermatopathology

Volumn 35, Issue 5, 2013, Pages 576-581

  Palla, Beth ^a   Su, Albert ^a   Binder, Scott ^a   Dry, Sarah ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

SOX10, desmoplastic melanoma, dermal spindle cell lesions, immunohistochemistry

Indexed keywords

TRANSCRIPTION FACTOR SOX10;

ARTICLE; CELL STRUCTURE; DERMIS; DESMOPLASTIC MELANOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALIGNANT PERIPHERAL NERVE SHEATH TUMOR; MYXOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SARCOMA; SPINDLE CELL; SUBCUTANEOUS TISSUE; UNDIFFERENTIATED CARCINOMA;

BIOPSY; CARCINOMA; CELL DIFFERENTIATION; DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNOHISTOCHEMISTRY; MELANOMA; NERVE SHEATH NEOPLASMS; PREDICTIVE VALUE OF TESTS; SARCOMA; SKIN NEOPLASMS; SOXE TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84880572520     PISSN: 01931091     EISSN: 15330311     Source Type: Journal    
DOI: 10.1097/DAD.0b013e31827a0b98     Document Type: Article

References (30)

1. Nonaka D, Chiriboga L, Rubin BP. Sox10: a pan-schwannian and melanocytic marker. Am J Surg Pathol. 2008;32:1291-1298.
2. Bakos RM, Maier T, Besch R, et al. Nestin and SOX9 and SOX10 transcription factors are coexpressed in melanoma. Exp Dermatol. 2010;19:89-94.
3. Ramos-Herberth FI, Karamchandani J, Kim J, et al. SOX10 immunostaining distinguishes desmoplastic melanoma from excision scar. J Cutan Pathol. 2010;37:944-952.
4. Weiss SW, Goldblum JR, Malignant fibrous histiocytoma (pleomorphic undifferentiated sarcoma). In: Weiss SW, Goldblum JR, eds. Enzinger and Weiss's soft tissue tumors. 5th ed. Mosby Elsevier; 2008: 403-427.
5. Hong CS, Saint-Jeannet JP. Sox proteins and neural crest development. Semin Cell Dev Biol. 2005;16:694-703.
6. Schepers GE, Teasdale RD, Koopman P. Twenty pairs of sox: extent, homology, and nomenclature of the mouse and human sox transcription factor gene families. Dev Cell. 2002;3:167-170.
7. Harley VR, Lovell-Badge R, Goodfellow PN. Definition of a consensus DNA binding site for SRY. Nucleic Acids Res. 1994;22:1500-1501.
8. Bondurand N, Pingault V, Goerich DE, et al. Interaction among SOX10, PAX3 and MITF, three genes altered in Waardenburg syndrome. Hum Mol Genet. 2000;9:1907-1917.
9. Verastegui C, Bille K, Ortonne JP, et al. Regulation of the microphthalmiaassociated transcription factor gene by the Waardenburg syndrome type 4 gene, SOX10. J Biol Chem. 2000;275:30757-30760.
10. Elworthy S, Lister JA, Carney TJ, et al. Transcriptional regulation of mitfa accounts for the sox10 requirement in zebrafish melanophore development. Development. 2003;130:2809-2818.
11. Lang D, Epstein JA. Sox10 and Pax3 physically interact to mediate activation of a conserved c-RET enhancer. Hum Mol Genet. 2003;12: 937-945.
12. Jiao Z, Mollaaghababa R, Pavan WJ, et al. Direct interaction of Sox10 with the promoter of murine Dopachrome Tautomerase (Dct) and synergistic activation of Dct expression with Mitf. Pigment Cell Res. 2004;17: 352-362.
13. Murisier F, Guichard S, Beermann F. A conserved transcriptional enhancer that specifies Tyrp 1 expression to melanocytes. Dev Biol. 2006;298:644-655.
14. Murisier F, Guichard S, Beermann F. The tyrosinase enhancer is activated by Sox10 and Mitf in mouse melanocytes. Pigment Cell Res. 2007; 20:173-184.
15. Pingault V, Bondurand N, Kuhlbrodt K, et al. SOX10 mutations in patients with Waardenburg-Hirschsprung disease. Nat Genet. 1998;18: 171-173.
16. Bondurand N, Kuhlbrodt K, Pingault V, et al. A molecular analysis of the Yemenite deaf-blind hypopigmentation syndrome: SOX10 dysfunction causes different neurocristopathies. Hum Mol Genet. 1999;8:1785-1789.
17. Inoue K, Khajavi M, Ohyama T, et al. Molecular mechanism for distinct neurological phenotypes conveyed by allelic truncating mutations. Nat Genet. 2004;36:361-369.
18. Sigel JE, Skacel M, Bergfeld WF, et al. The utility of cytokeratin 5/6 in the recognition of cutaneous spindle cell squamous cell carcinoma. J Cutan Pathol. 2001;28:520-524.
19. Buonaccorsi JN, Plaza JA. Role of CD10, wide-Spectrum keratin, p63, and Podoplanin in the distinction of epithelioid and spindle cell tumors of the skin: an immunohistochemical study of 81 cases. Am J Dermatopathol. 2012;34:404-411.
20. Wieland CN, Dyck R, Weenig RH, et al. The role of CD10 in distinguishing atypical fibroxanthoma from sarcomatoid (spindle cell) squamous cell carcinoma. J Cutan Pathol. 2011;38:884-888.
21. Hall JM, Saenger JS, Fadare O. Diagnostic utility of P63 and CD10 in distinguishing cutaneous spindle cell/sarcomatoid squamous cell carcinomas and atypical fibroxanthomas. Int J Clin Exp Pathol. 2008;1:524-530.
22. Hultgren TL, DiMaio DJ: Immunohistochemical staining of CD10 in atypical fibroxanthomas. J Cutan Pathol. 2007;34:415-419.
23. Kanik AB, Yaar M, Bhawan J. P75 nerve growth factor receptor staining helps identify desmoplastic and neurotropic melanoma. J Cutan Pathol. 1996;23:205-210.
24. Kossard S, Doherty E, Murray E. Neurotropic melanoma: a variant of desmoplastic melanoma. Arch Dermatol. 1987:123:907.
25. Argenyi ZB, Cain C, Bromley C, et al. S-100 protein-negative malignant melanoma: fact or fiction? A light-microscopic and immunohistochemical study. Am J Dermatopathol. 1994;16:233-240.
26. Szollosi Z, Nemes Z. Transformed dermatofibrosarcoma protuberans: a clinicopathological study of eight cases. J Clin Pathol. 2005;58: 751-756.
27. Kaufmann O, Koch S, Burghardt J, et al. Tyrosinase, melan-A, and KBA62 as markers for the immunohistochemical identification of metastatic amelanotic melanomas on paraffin sections. Mod Pathol. 1998;11: 740-746.
28. Aung PP, Sarlomo-Rikala M, Lasota J, et al. KBA62 and PNL2: 2 new melanoma markers-immunohistochemical analysis of 1563 tumors including metastatic, desmoplastic, and mucosal melanomas and their mimics. Am J Surg Pathol. 2012;36:265-272.
29. Cohen-Knafo E, al Saati T, Aziza J, et al. Production and characterization of an antimelanoma monoclonal antibody KBA.62 using a new melanoma cell line reactive on paraffin wax embedded sections. J Clin Pathol. 1995;48:826-831.
30. Bernaba BN, Vogiatzis PI, Binder SW, et al. Potentially useful markers for desmoplastic melanoma: an analysis of KBA.62, p-AKT, and Ezrin. Am J Dermatopathol. 2011;33:333-337.